Developments in the treatment of candidiasis: more choices and new challenges

被引：38

作者：

Aperis, George ^{[1
]}

Myriounis, Nikolaos ^{[1
]}

Spanakis, Elias K. ^{[1
]}

Mylonakis, Eleftherios ^{[1
]}

机构：

[1] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2006年 / 15卷 / 11期

关键词：

anidulafungin; BAL4815; Candida; candidaemia; candidiasis; caspofungin; FK463; L-743872; LY303366; micafungin; MK-0991; posaconazole; SCH56592; UK-109496; voriconazole;

D O I：

10.1517/13543784.15.11.1319

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The incidence of oesophageal candidiasis, candidaemia and disseminated candidiasis has increased dramatically. In addition to the amphotericin B formulations and fluconazole, the echinocandins anidulafungin, caspofungin and micafungin and the newer triazoles posaconazole and voriconazole are in the last stages of development and are becoming available for the management of candidiasis. This review presents these new agents and addresses their role in the treatment of candidiasis. All new antifungal agents exhibit potent activity against Candida spp. and echinocandins are fungicidal against most Candida spp. but appear to be less potent against certain species, such as Candida parapsilosis and C. guilliermondii. Systemic antifungal therapy can now be individualised based on the severity of the infection, comorbid conditions and the Candida spp. causing the infection. Studies are needed to investigate the possible development of resistance and the efficacy of these antifungal agents against the more resistant Candida spp.

引用

页码：1319 / 1336

页数：18

共 102 条

[1] A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients [J].

Ally, R ;

Schürmann, D ;

Kreisel, W ;

Carosi, G ;

Aguirrebengoa, K ;

Dupont, B ;

Hodges, M ;

Troke, P ;

Romero, AJ .

CLINICAL INFECTIOUS DISEASES, 2001, 33 (09) :1447-1454

[2] Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations [J].

Aperis, George ;

Mylonakis, Eleftherios .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2006, 15 (06) :579-602

[3] Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata [J].

Barchiesi, F ;

Spreghini, E ;

Tomassetti, S ;

Arzeni, D ;

Giannini, D ;

Scalise, G .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (12) :4989-4992

[4] In vitro studies of two triazole antifungal agents (Voriconazole [UK-109,496] and fluconazole) against Candida species [J].

Barry, AL ;

Brown, SD .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) :1948-1949

[5] In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872) [J].

Bartizal, K ;

Gill, CJ ;

Abruzzo, GK ;

Flattery, AM ;

Kong, L ;

Scott, PM ;

Smith, JG ;

Leighton, CE ;

Bouffard, A ;

Dropinski, JF ;

Balkovec, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (11) :2326-2332

[6] In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida [J].

Cacciapuoti, A ;

Loebenberg, D ;

Corcoran, E ;

Menzel, F ;

Moss, EL ;

Norris, C ;

Michalski, M ;

Raynor, K ;

Halpern, J ;

Mendrick, C ;

Arnold, B ;

Antonacci, B ;

Parmegiani, R ;

Yarosh-Tomaine, T ;

Miller, GH ;

Hare, RS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (08) :2017-2022

[7] Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii [J].

Canton, Emilia ;

Peman, Javier ;

Sastre, Macrina ;

Romero, Monica ;

Espinel-Ingroff, Ana .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (08) :2829-2832

[8] Antifungal activity of posaconazole compared with fluconazole and amphotericin B against yeasts from oropharyngeal candidiasis and other infections [J].

Carrillo-Muñoz, AJ ;

Quindós, G ;

Ruesga, M ;

Alonso, R ;

del Valle, O ;

Hernández-Molina, JM ;

McNicholas, P ;

Loebenberg, D ;

Santos, P .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (03) :317-319

[9] In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients [J].

Chávez, M ;

Bernal, S ;

Valverde, A ;

Gutierrez, MJ ;

Quindós, G ;

Mazuelos, EM .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (05) :697-700

[10] Assessment of the paradoxical effect of caspofungin in therapy of candidiasis [J].

Clemons, KV ;

Espiritu, M ;

Parmar, R ;

Stevens, DA .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (04) :1293-1297

← 1 2 3 4 5 6 7 8 9 10 →